HMG — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

HMG (Human Menopausal Gonadotropin)

Also known as: hMG, HP-hMG, highly purified hMG, human menopausal gonadotrophin, menotropins, Menopur

Gonadotropin / Fertility hormone preparation (NOTE: The abbreviation "HMG" in the provided literature also refers to multiple distinct biological entities: High

Research chemicalLast updated: October 31, 2026Based on 14 peer-reviewed studies

What it is

HMG (Human Menopausal Gonadotropin) is a fertility hormone preparation used in IVF and ovulation induction treatments to stimulate egg production. It works by delivering the hormones FSH and LH to drive follicle development in the ovaries. Approved for clinical fertility use in multiple countries; not available as a self-administered research compound.

The scientific side

Human menopausal gonadotropin (hMG) is a preparation containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity (with highly purified formulations, HP-hMG, having human chorionic gonadotropin constituting most of its LH-like activity) used to stimulate ovarian follicle development. In controlled ovarian stimulation for IVF/ICSI, hMG promotes follicular growth and maturation. The abbreviation "HMG" in broader scientific literature also denotes: (1) High Mobility Group (HMG) proteins — a superfamily of abundant nuclear proteins that bind DNA and nucleosomes, induce structural changes in the chromatin fiber, and modulate transcription, replication, and other DNA-dependent processes; and (2) HMG-CoA reductase — the enzyme catalyzing the rate-limiting step in cholesterol/isoprenoid biosynthesis (conversion of HMG-CoA to mevalonate), which is the pharmacological target of statins.

Class: Gonadotropin / Fertility hormone preparation (NOTE: The abbreviation "HMG" in the provided literature also refers to multiple distinct biological entities: High Mobility Group proteins (chromatin-associated nuclear proteins), HMG-CoA reductase (an enzyme in cholesterol biosynthesis), and human menopausal gonadotropin (a fertility drug). This record focuses primarily on human menopausal gonadotropin (hMG) as a therapeutic agent, given the plurality of clinical/pharmacological abstracts. HMG-box protein and HMG-CoA reductase topics are noted separately.)

Administration & storage

Administration
Intramuscular injection — hMG in Japanese Black cattle superovulation study (PMID: 8720060)Subcutaneous injection — pulsatile GnRH component of modified hMG-GnRH protocol (20 µg/120 min SC) (PMID: 12081234)Injection (route not further specified) — hMG in FET endometrial preparation studies (PMID: 31814708PMID: 29676585)Injection (route not further specified) — hMG/HP-hMG in IVF/ICSI COS studies (PMID: 18583332PMID: 21776876PMID: 19298714)
Storage
No storage conditions for hMG preparations are described in the provided abstracts.
Cautions
Ovarian hyperstimulation syndrome (OHSS) has been reported with hMG-based protocols; the conventional hMG-hCG method was associated with a 25.7% OHSS rate in one study of hypogonadotropic amenorrhea patients, compared to 0% with a modified protocol.,Multiple pregnancy risk is associated with hMG stimulation; more than eight growing follicles were observed with the conventional hMG-hCG method in one study.,One abstract cited as a source for sequential CC/hMG vs hMG protocols is listed as a Retracted Publication — findings from this study should be interpreted with caution.,HP-hMG and traditional hMG preparations differ in purity and LH-activity source (hCG constitutes most LH-like activity in HP-hMG); clinical outcomes may differ between formulations (PMID: 19298714, PMID: 20500109).,Sterile technique is essential for any injectable preparation.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification